GSK, Moderna and mRNA
GSK sues Moderna over mRNA vaccine technology
GlaxoSmithKline is suing Moderna for allegedly using technology patented by GSK in its COVID-19 vaccine. Why it matters: It's the latest in a series of legal fights over who owns the intellectual property behind mRNA technology and whether some companies are entitled to royalties on future sales.
GSK sues Moderna for US patent infringement over COVID, RSV vaccines
British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing its American rival of violating GSK's patent rights in messenger RNA (mRNA) technology with its blockbuster COVID-19 vaccine Spikevax.
GSK takes mRNA patent fight to Moderna, suing over vaccines for COVID and RSV
Nearly six months after lodging a similar complaint against Pfizer and BioNTech over the partners’ COVID shot Comirnaty, GSK is targeting Moderna in a pair of lawsuits alleging the Massachusetts-ba | GSK is targeting Moderna in a pair of lawsuits claiming the mRNA specialist violated multiple patents with its vaccines Spikevax and mRESVIA.
Northwestern sues Moderna for alleged patent infringement in COVID shots
Moderna is facing allegations that it misused innovations from researchers at Northwestern University to develop its mRNA COVID-19 vaccines, which became widely available to the public in 2021 to combat the pandemic.
Northwestern sues Moderna for patent infringement over COVID-19 vaccines
Moderna was hit with a new patent lawsuit on Wednesday in Delaware federal court from Northwestern University, which accused the company of misusing the school's innovations to develop its blockbuster COVID-19 vaccine Spikevax.
British drugmaker sues Moderna for patent infringement related to mRNA vaccines
A British drugmaker, GlaxoSmithKline (GSK), has sued American pharmaceutical company Moderna claiming it violated patent rights in its mRNA technology used to develop its COVID-19 and RSV vaccines.
GlobalData on MSN15h
mRNA licensing agreements surge 800% amid GSK lawsuits
It follows a similar lawsuit against Pfizer and BioNTech filed in April in which GSK alleges the companies were in violation ...
Zacks Research Issues Pessimistic Forecast for GSK Earnings
Research analysts at Zacks Research reduced their Q1 2026 EPS estimates for shares of GSK in a report issued on Wednesday, ...
GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 billion
GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of ...
GSK rises Thursday, still underperforms market
GSK PLC GSK shares inched up 0.03% to £14.97 Thursday, on what proved to be an all-around favorable trading session for the ...
FierceBiotech2d
Wave hails first for human RNA editing with GSK-partnered prospect, sending stock skyward
Wave Life Sciences has taken a step toward validating a new modality, becoming the first group to report therapeutic RNA ...
GSK to Pay Over $2 Billion in Bid to End Most U.S. Zantac Lawsuits
GSK agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its ...
GSK Seeks FDA Approval For Oral Antibiotic For Urinary Tract Infections, Probably First In New Class In Over 20 Years
GSK's gepotidacin, an oral antibiotic for uUTIs, could be the first in over 20 years. The FDA granted Priority Review with a ...
GSK shares jump on $2.2 billion Zantac settlement
GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits ...
GSK Says Potential Blockbuster Helps Treat Common Nasal Disease
GSK Plc’s experimental drug to treat a common inflammatory nasal condition showed positive results in two late-stage trials ...
FierceBiotech20h
GSK and Boston scientists team up to study pulmonary fibrosis and develop new treatments
London-based GSK is crossing the pond to form a new lung disease research collaboration with Boston scientists. | ...